HCAT
$1.17
Health Catalyst, Inc.
Recent News
HCAT Q4 Deep Dive: Margin Focus and Strategic Review Amid Platform Migration Pressures
Healthcare data analytics company Health Catalyst (NASDAQ:HCAT) beat Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 6.2% year on year to $74.68 million. On the other hand, next quarter’s revenue guidance of $69 million was less impressive, coming in 7.9% below analysts’ estimates. Its non-GAAP profit of $0.08 per share was 16.1% below analysts’ consensus estimates.
Health Catalyst (HCAT) Q4 2025 Earnings Transcript
Matt Hopper: Which ended 12/31/2025. My name is Matt Hopper, Senior Vice President of Finance and Head of Investor Relations. With me on the call today are Ben Albert, our Chief Executive Officer, and Jason Alger, our Chief Financial Officer.
Health Catalyst Inc (HCAT) Q4 2025 Earnings Call Highlights: Navigating Revenue Challenges and ...
Despite a dip in quarterly revenue, Health Catalyst Inc (HCAT) reports strong EBITDA growth and outlines strategic plans to enhance market alignment and operational efficiency.
Health Catalyst Q4 Earnings Call Highlights
Health Catalyst (NASDAQ:HCAT) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline a leadership transition, discuss the financial impact of continued restructuring and platform migrations, and preview changes to how the company will communicate performance metrics
Health Catalyst (HCAT) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Health Catalyst (HCAT) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.